1-{1-[(tert-butoxy)carbonyl]piperidin-3-yl}-1H-pyrazole-4-carboxylic acid

Catalog No. :
ACSGZT991
CAS No. :
1422386-02-4
Molecular Formula :
C14H21N3O4
Molecular Weight :
295.34

IUPAC Name:1-(1-(tert-butoxycarbonyl)piperidin-3-yl)-1H-pyrazole-4-carboxylic acid

1-{1-[(tert-butoxy)carbonyl]piperidin-3-yl}-1H-pyrazole-4-carboxylic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg98%$142.00Login to see priceInquiryInquiry
100mg98%$204.00Login to see priceInquiryInquiry
250mg98%$281.00Login to see priceInquiryInquiry
1g98%$552.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-{1-[(tert-butoxy)carbonyl]piperidin-3-yl}-1H-pyrazole-4-carboxylic acid
IUPAC Name1-(1-(tert-butoxycarbonyl)piperidin-3-yl)-1H-pyrazole-4-carboxylic acid
MDL No.MFCD25371800
Molecular FormulaC14H21N3O4
Molecular Weight295.34
SMILESO=C(C1=CN(C2CN(C(OC(C)(C)C)=O)CCC2)N=C1)O
InChI KeyZTQAPANOXVJNDD-UHFFFAOYSA-N
Synonym1-(1-(tert-butoxycarbonyl)piperidin-3-yl)-1H-pyrazole-4-carboxylic acid;1-Piperidinecarboxylic acid, 3-(4-carboxy-1H-pyrazol-1-yl)-, 1-(1,1-dimethylethyl) ester;1-(1-(tert-Butoxycarbonyl)piperidin-3-yl)-1H-pyrazole-4-carboxylic acid
CAS No.1422386-02-4

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACSGZT991 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACSGZT991 route product structure diagram
    ACSGZT9911422386-02-4
Inquiry

2. ACSGZT991 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACSGZT991 route product structure diagram
    ACSGZT9911422386-02-4
Inquiry

Comments (0)